Opinion: America’s Illicit Weight-Loss Drug Market Is a Public Health Threat

     America’s booming demand for weight-loss drugs has created a dangerous new black market — one that threatens patient safety, undermines trust in medicine, and exposes alarming weaknesses in federal oversight. Congress and federal regulators must act immediately to stop the flood of illegal and unapproved imitation GLP-1 drugs entering the United States before more Americans are harmed.

     Across the country, patients seeking popular weight-loss medications such as semaglutide and tirzepatide are increasingly turning to online sellers and rogue pharmacies promising fast access at lower prices. Many consumers believe they are purchasing legitimate “pharmaceutical-grade” medications comparable to FDA-approved treatments. In reality, many are unknowingly buying research-grade substances imported from overseas facilities, often located in China and potentially operating outside the reach of U.S. regulators.

     Some of these products explicitly state they are intended “for laboratory research purposes only” and “not for human or animal use.” Yet these same substances are reportedly being injected into patients across the United States. That should alarm every American.

    Counterfeit medications are not a victimless crime. They are a direct threat to public health and national security. Patients who purchase these imitation drugs have no reliable way of knowing what they are putting into their bodies. The ingredients may be contaminated, improperly dosed, or entirely different from what is advertised. In the best-case scenario, these drugs simply fail to work. In the worst-case scenario, they can cause severe medical complications, permanent injury, or death.

    The problem has grown so large that leading public health experts are sounding the alarm. A recent report from the Center for Medicine in the Public Interest (CMPI) found that regulators, including the Food and Drug Administration, have failed to adequately stop the mass production and importation of illegal compounded GLP-1 drugs. According to the report, dangerous ingredients are flowing into compounding pharmacies that then market these products directly to patients, often without sufficient transparency about sourcing or safety.

     Peter J. Pitts, former FDA Associate Commissioner and current CMPI president, described the situation bluntly: “The FDA is allowing a black market of pharmaceutical-grade knockoffs to thrive right under its nose. This is not just regulatory negligence — it’s a public health crisis in the making.”

     Unfortunately, many Americans cannot distinguish between legitimate pharmacies and sophisticated online operations designed to look credible. Rogue sellers exploit shortages of approved GLP-1 medications, using aggressive marketing tactics and high-pressure sales techniques to lure vulnerable consumers desperate to lose weight or manage diabetes. Sleek websites, fake credentials, and misleading claims create the illusion of legitimacy while concealing serious risks.

    This issue goes beyond consumer fraud. Every counterfeit or illegally compounded medication erodes public confidence in America’s healthcare system and damages trust in legitimate pharmaceutical providers that follow rigorous safety standards. Patients deserve confidence that medications sold in the United States meet established standards for quality, purity, and effectiveness.

    Congress cannot afford to ignore this growing threat. Federal lawmakers should strengthen oversight of imported pharmaceutical ingredients, increase penalties for illegal online drug sellers, and provide regulators with the resources necessary to identify and shut down illicit supply chains. Customs enforcement must also be strengthened to prevent dangerous substances from entering American communities in the first place.

     At the same time, regulators should improve public education so consumers understand the difference between FDA-approved medications and unapproved research compounds masquerading as legitimate therapies.

     The promise of innovative weight-loss drugs should not become an opportunity for criminals and bad actors to exploit patients. Americans seeking better health should never be forced to gamble with counterfeit medications and unknown substances sold online.

     The time for warnings has passed. Congress and federal agencies must act swiftly and decisively to stop illicit GLP-1 drugs from flooding the market and hold unscrupulous sellers accountable before this growing crisis claims more victims.

Robert J. Bodisch Sr. is a retired deputy director and chief of staff of the Texas Department of Public Safety and Texas Homeland Security, a retired major general and former commanding general of the Texas State Guard, and a senior fellow at the Center for Security Policy.